Pluristem Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on April 15, 2019, by Pluristem Therapeutics Inc., a Nevada corporation headquartered in Haifa, Israel. The report addresses a regulatory notice received on April 11, 2019, regarding the company's listing status on the Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on compliance with Nasdaq listing standards rather than financial performance metrics.
Material Changes
The material change reported is the receipt of a written notice from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2). The company's common stock closing bid price fell below $1.00 per share for 30 consecutive business days ending April 11, 2019.
Outlook, Risks, and Management Commentary
- Compliance Period: Nasdaq has granted a 180-calendar day compliance period, expiring on October 8, 2019, to regain compliance.
- Requirement to Cure: To maintain listing, the closing bid price must meet or exceed $1.00 per share for at least 10 consecutive business days within the compliance period.
- Delisting Risk: If compliance is not achieved by the deadline, the stock may be subject to delisting.
- Extension Possibility: A second 180-day compliance period may be available if the company meets all other initial listing standards (excluding bid price) and provides written notice of intent to cure.
- Management Action: The company intends to monitor the stock price and consider available options to resolve the non-compliance.
Investor Verification Checklist
- Verify the current closing bid price of Pluristem Therapeutics Inc. common stock relative to the $1.00 threshold.
- Monitor the company's progress toward achieving 10 consecutive days of compliance before the October 8, 2019 deadline.
- Review subsequent filings for any announcements regarding reverse stock splits or other capital structure changes intended to address the bid price deficiency.
- Check for any updates on the company's ability to meet other Nasdaq initial listing standards if a second compliance period is sought.